We suggest that activation of alternative signaling pathways is a possible molecular mechanism of drug resistance in NSCLC, utilizing c-Met, EGFR, mTOR and Wnt inhibitors could greatly improve lung cancer patient prognosis and be the basis for new clinical trials. This evidence concerns the gene EGFR and non-small cell lung carcinoma.